Key Takeaways
- UNH began trading at $277.32, significantly below its 52-week peak of $606.36
- Several Wall Street firms reduced price targets — JPMorgan to $389, Truist to $370, UBS to $410
- Weiss Ratings issued a Sell rating for UNH in early March
- Fourth quarter EPS of $2.11 edged past forecasts; revenue climbed 12.3% to $113.73 billion
- MarketBeat consensus shows Moderate Buy with average price target of $372.13
UnitedHealth Group (UNH) has encountered significant headwinds recently. Shares opened Monday at $277.32, trading substantially beneath the 50-day moving average of $297.19 and the 200-day moving average of $324.39.
This represents a dramatic decline from the stock’s 52-week peak of $606.36. The annual low point reached $234.60.
The healthcare giant’s market capitalization currently registers at $251.71 billion, accompanied by a P/E ratio of 21.02 and a beta measurement of 0.41.
The company reports a debt-to-equity ratio of 0.72, while both current and quick ratios stand at 0.79.
During January, UnitedHealth disclosed fourth quarter earnings of $2.11 per share, narrowly exceeding the $2.09 Wall Street consensus. Revenue reached $113.73 billion, marking a 12.3% year-over-year increase and modestly surpassing analyst projections.
However, the Q4 EPS figure represents a substantial decline compared to the $6.81 posted during the corresponding quarter of the previous year.
Wall Street Firms Lower Price Projections
Numerous prominent financial institutions have reduced their price objectives in recent weeks.
JPMorgan decreased its target from $425 down to $389, Morgan Stanley adjusted theirs from $411 to $409, and UBS reduced their projection from $430 to $410. Truist implemented the most aggressive reduction, slashing from $410 to $370. Despite these cuts, all four firms maintained Buy or Overweight recommendations.
Weiss Ratings took a more bearish stance, downgrading UNH from Hold to Sell during early March.
MarketBeat’s current consensus rating stands at Moderate Buy, featuring 17 Buy recommendations, 8 Hold ratings, and 2 Sell ratings. The average 12-month price objective sits at $372.13 — suggesting approximately 34% potential upside from present levels.
Regarding institutional activity, significant movements have occurred. Wealth Enhancement Advisory Services reduced its position by 40.6% during Q4, divesting 170,643 shares. Conversely, Norges Bank, Berkshire Hathaway, and Capital Research Global Investors either increased or established new positions throughout 2024. Institutional investors collectively control 87.86% of outstanding shares.
Ongoing Regulatory Challenges
Department of Justice investigations concerning Medicare Advantage reimbursement methodologies continue impacting investor confidence. While the company has secured at least one favorable legal outcome in related litigation, broader regulatory pressures surrounding prior-authorization protocols and coverage denial practices persist.
Company leadership has previously disclosed strategies to reduce certain Medicare Advantage enrollees and adjust product pricing in response to changing cost dynamics.
Management issued FY2026 EPS guidance of approximately $17.75. Wall Street analysts currently project full-year EPS of $29.54 for the ongoing fiscal year.
UNH distributed a quarterly dividend of $2.21 per share on March 17, yielding approximately 3.2% on an annualized basis. The current payout ratio measures 67.02%.
On a constructive note, UnitedHealth recently unveiled a nationwide expansion of its doula benefit program, which may enhance member retention rates and deliver improved outcomes within its value-based care framework.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
